ESOR Navigation

Course Moderator / Coordinator

M.-P Revel


Registration information

All ESOR Foundation Courses are included in the ESR Premium Education Package.

The ESR Premium Education Package includes access to numerous educational services such as Education on Demand, Eurorad, and content on ESR Connect.


CME accreditation
ONLY for Live Streaming

An application for European CME credits (ECMEC) is submitted to the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS),

 No CME credits will be available for watching on demand.

ESOR Foundation Course

CHEST IMAGING | Online | May , 2023 | 12:30 – 18:30 CEST

Course Information

This course is aimed at residents in their 4th and 5th year of training in radiology and recently board-certified radiologists interested in Chest Imaging. It is strictly adhered to Level II of the European Training Curriculum and is designed to provide the essentials of current state-of the-art imaging, diagnostic algorithms and their appropriateness, in the initial staging of lung cancer and follow-up of systemic therapies. It is also important to become familiar with atypical presentations of lung cancer and the management of incidental findings in thoracic oncology. CT has a major role in patients with severe haemoptysis, a potentially life-threatening condition. Finally, CT can approach the accurate diagnosis of diffuse cystic disease of the lung.

Learning objectives

  • To learn about initial CT staging, management of incidental findings and assessment of response to treatment on CT in lung cancer patients

  • To learn how CT helps reduce differential diagnoses in cystic lung disease.

  • To learn about the role of CT in patients with severe haemoptysis

Programme Online

Wednesday, May 10, 2023



Lung cancer: initial staging and TNM classification

A.R Larici, Rome/IT


Lung cancer: atypical presentations

I. Hartmann, Rotterdam/NL


Haemoptysis: what is the role of CT?

M.-P Revel, Paris/FR






Response to systemic therapy: RECIST and Irecist criteria, pulmonary toxicity.  

A.R Larici, Rome/IT


Incidental findings in thoracic oncology

I. Hartmann, Rotterdam/NL


Cystic lung diseases: easy to diagnose!

M.-P Revel, Paris/FR